Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy  Bjoern Hoffmann, Martin Schwarz, Atul Mehta, Satish Keshav  Clinical Gastroenterology and Hepatology  Volume 5, Issue 12, Pages 1447-1453 (December 2007) DOI: 10.1016/j.cgh.2007.08.012 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Reported prevalence of gastrointestinal symptoms in 342 patients with Fabry disease: more than 50% of patients with Fabry disease reported gastrointestinal symptomatology before the initiation of ERT. The most prevalent symptoms were abdominal pain and diarrhea. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Median age at onset of gastrointestinal symptoms in 292 patients with Fabry disease. Gastrointestinal symptoms were reported at an early stage. For comparison, mean age of onset of acroparaesthesia, as the leading symptom in Fabry disease, is 9 years. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 Reported changes in prevalence of abdominal pain after 12 months of ERT with agalsidase alfa; numbers in brackets represent the number of evaluable patients with relevant data on gastrointestinal symptomatology at baseline and after 12 months of therapy. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions

Figure 4 Reported changes in prevalence of diarrhea after 12 months of ERT with agalsidase alfa; numbers in brackets represent number of evaluable patients with relevant data on gastrointestinal symptomatology at baseline and at 12 months. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions

Figure 5 Reported changes in prevalence of abdominal pain after 24 months of ERT with agalsidase alfa; numbers in brackets represent number of evaluable patients with relevant data on gastrointestinal symptomatology at baseline and at 24 months. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions

Figure 6 Reported changes in prevalence of diarrhea after 24 months of ERT with agalsidase alfa; numbers in brackets represent number of evaluable patients with relevant data on gastrointestinal symptomatology at baseline and at 24 months. Clinical Gastroenterology and Hepatology 2007 5, 1447-1453DOI: (10.1016/j.cgh.2007.08.012) Copyright © 2007 AGA Institute Terms and Conditions